Lung Cancer News

E-Cigarette Smoke Causes Lung Cancer in Mice (October 8, 2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC (October 4, 2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC (September 27, 2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the... Continue Reading

FDA Approves Keytruda for Small Cell Lung Cancer (June 18, 2019)

The  Food and Drug Administration granted accelerated approval to Keytruda (pembrolizumab) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of... Continue Reading

Lorbrena Approved for second- or third-line treatment of ALK-positive metastatic NSCLC (November 8, 2018)

The US Food and Drug Administration granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on (Xalkori... Continue Reading

FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC (November 5, 2018)

On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed... Continue Reading

November Is National Lung Cancer Awareness Month (October 23, 2018)

Treatment advances – lung cancer resources and advocacy are making the difference The month of November brings lung cancer into focus. Over the past few years great strides have been made in the treatment of non-small cell lung cancer due to the... Continue Reading

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone (October 15, 2018)

Penn study shows patients with treatable mutations identified by liquid biopsy also largely respond to therapy October 11, 2018 PHILADELPHIA – In one of the largest clinical studies to ever examine the impact of using a blood test to detect treatable... Continue Reading

Immune-mediated Nephritis Reported to Occur with Tecentriq® (August 30, 2018)

Immune-mediated Nephritis Reported to Occur with Tecentriq® Enough patients have developed immune-mediated nephritis which has been biopsy-confirmed in many cases that the manufacturer of Tecentriq now considers this to be an important adverse reaction. ... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (July 10, 2018)

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless... Continue Reading

Latest Lung Cancer News By Stage


General Lung Cancer

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Keytruda® Active in Small Cell Lung Cancer (December 27, 2016)

Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading

Personalized Lung Cancer Care & Precision Medicine (November 8, 2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

More General Lung Cancer